Surgery Partners

SGRYNASDAQUSD

THESIS ALERT

Email me when the SGRY thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$26.66
−$0.07 (−0.26%)Today 1M +92.44%
After hours$26.60−0.23%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$26.73
Prior regular-session close from the quote source.
$26.39–$26.70
Regular-session low and high so far today.
2.6M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$11.41–$27.23
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own SGRY if Surgery Partners is a levered outpatient-surgery network whose equity value depends on converting the secular shift from hospitals to ambulatory surgical facilities into parent-level cash earnings, not just larger reported revenue.

SGRY price history

Latest price$26.66Today−$0.07 (-0.26%)
SGRY +90.97%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break.StrengtheningMateriality: High

    Item 1 Business description says Surgery Partners owns and operates a national network of surgical facilities and ancillary services. If this holds, the company has a structural demand tailwind; if it breaks, revenue growth becomes acquisition-dependent and less valuable.

    Watch: Large hospital systems retain or recapture surgical specialists through employment models and direct case flow back to hospital outpatient departments.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Item 1 Business description says Surgery Partners owns and operates a national network of surgical facilities and ancillary services.

    Open source ↗
  • Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation.HoldingMateriality: High

    GAAP annual operating income increased from $302.2 million in FY2021 to $389.5 million in FY2025. Revenue growth only creates value if the company keeps enough of each incremental case after clinical staffing, supplies, and payer friction.

    Watch: Nurse, anesthesiology, and surgical technician shortages force sustained wage increases that cannot be passed through to payers.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income increased from $302.2 million in FY2021 to $389.5 million in FY2025.

    Open source ↗
  • Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses.StrengtheningMateriality: Medium

    GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025. Positive operating cash flow gives the company room to invest and manage leverage; weak cash conversion would turn the roll-up model into a financing problem.

    Watch: Commercial payers or Medicare Advantage plans slow payments, increase denials, or require more prior authorizations for outpatient procedures.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025.

    Open source ↗
  • Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders.WeakeningMateriality: Medium

    Liabilities increased from $3.7412 billion at FY2022 year-end to $4.9884 billion at FY2025 year-end. This is the key equity-risk claim: the business can grow while the common stock still disappoints if debt service absorbs the improvement.

    Watch: Credit markets demand materially higher refinancing costs or tighter covenants for Surgery Partners’ debt.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Liabilities increased from $3.7412 billion at FY2022 year-end to $4.9884 billion at FY2025 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break. If this holds, the company has a structural demand tailwind; if it breaks, revenue growth becomes acquisition-dependent and less valuable.

Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation. Revenue growth only creates value if the company keeps enough of each incremental case after clinical staffing, supplies, and payer friction.

Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses. Positive operating cash flow gives the company room to invest and manage leverage; weak cash conversion would turn the roll-up model into a financing problem.

Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders. This is the key equity-risk claim: the business can grow while the common stock still disappoints if debt service absorbs the improvement.

All standing thesis claims
Original report summary

Surgery Partners is a levered outpatient-surgery network whose equity value depends on converting the secular shift from hospitals to ambulatory surgical facilities into parent-level cash earnings, not just larger reported revenue.

Evidence assessed Nov 12, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Surgery Partners

Where the evidence on Surgery Partners disagrees: Mixed on the latest evidence (Nov 12, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.

Bull case: what the evidence supports

  • The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break.

    sec.gov ↗

  • Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation.

    sec.gov ↗

  • Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses.

    sec.gov ↗

Bear case: what the evidence questions

  • Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Surgery Partners

Loading the break-condition record for Surgery Partners.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Surgery Partners filed an SEC 8-K on 2026-11-09: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Surgery Partners filed an SEC 8-K on 2026-11-09: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Entered a material definitive agreement.

    Surgery Partners filed an SEC 8-K on 2026-10-26: Entered a material definitive agreement. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Large hospital systems retain or recapture surgical specialists through employment models and direct case flow back to hospital outpatient departments.
  • Nurse, anesthesiology, and surgical technician shortages force sustained wage increases that cannot be passed through to payers.
  • Commercial payers or Medicare Advantage plans slow payments, increase denials, or require more prior authorizations for outpatient procedures.
  • Credit markets demand materially higher refinancing costs or tighter covenants for Surgery Partners’ debt.

SGRY news

Loading headlines…

Financial statements

SGRY income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

SGRY: quick answers

Which well-known investors own SGRY?
1 of the 37 well-known funds tracked here reported SGRY shares in their latest 13F filing. By share of the fund's portfolio: Oaktree Capital Management (Howard Marks), 0.2%. Fund portfolios

SGRY in well-known investors’ portfolios

1 of 37 funds reported SGRY shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Howard MarksOaktree Capital Management0.20%$14.5MNewQ2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.